Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Preprint in English | medRxiv | ID: ppmedrxiv-22279589

ABSTRACT

BACKGROUNDThe rising breakthrough infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, especially Omicron and its sub-lineages, have raised an urgent need to develop broad-spectrum vaccines against coronavirus disease 2019 (COVID-19). We have developed a mosaic-type recombinant vaccine candidate, named NVSI-06-09, having immune potentials against a broad range of SARS-CoV-2 variants. METHODSAn ongoing randomized, double-blind, controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of NVSI-06-09 as a booster dose in subjects aged 18 years and older from the United Arab Emirates (UAE), who had completed two or three doses of BBIBP-CorV vaccinations at least 6 months prior to the enrollment. The participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or BBIBP-CorV. The primary outcomes were immunogenicity and safety against SARS-CoV-2 Omicron variant, and the exploratory outcome was cross-immunogenicity against other circulating strains. RESULTSA total of 516 participants received booster vaccination. Interim results showed a similar safety profile between NVSI-06-09 and BBIBP-CorV booster groups, with low incidence of adverse reactions of grade 1 or 2. For immunogenicity, by day 14 after the booster vaccination, the fold rises in neutralizing antibody geometric mean titers (GMTs) from baseline level elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain (19.67 vs 4.47-fold), Omicron BA.1.1 (42.35 vs 3.78-fold), BA.2 (25.09 vs 2.91-fold), BA.4 (22.42 vs 2.69-fold), and BA.5 variants (27.06 vs 4.73-fold). Similarly, the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those boosted by BBIBP-CorV. CONCLUSIONSA booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against SARS-CoV-2 prototype strain and immune-evasive variants, including Omicron and its sub-lineages. The immunogenicity of NVSI-06-09 as a booster vaccine was superior to that of BBIBP-CorV. (Funded by LIBP and BIBP of Sinopharm; ClinicalTrials.gov number, NCT05293548).

2.
Angewandte Chemie ; 134(32), 2022.
Article in English | ProQuest Central | ID: covidwho-1981566

ABSTRACT

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated (Cas) systems have recently received notable attention for their applications in nucleic acid detection. Despite many attempts, the majority of current CRISPR‐based biosensors in infectious respiratory disease diagnostic applications still require target preamplifications. This study reports a new biosensor for amplification‐free nucleic acid detection via harnessing the trans‐cleavage mechanism of Cas13a and ultrasensitive graphene field‐effect transistors (gFETs). CRISPR Cas13a‐gFET achieves the detection of SARS‐CoV‐2 and respiratory syncytial virus (RSV) genome down to 1 attomolar without target preamplifications. Additionally, we validate the detection performance using clinical SARS‐CoV‐2 samples, including those with low viral loads (Ct value >30). Overall, these findings establish our CRISPR Cas13a‐gFET among the most sensitive amplification‐free nucleic acid diagnostic platforms to date.

3.
Angewandte Chemie (International ed. in English) ; 61(32), 2022.
Article in English | EuropePMC | ID: covidwho-1980079

ABSTRACT

Nucleic acid detection plays a critical role in medical diagnostics, environmental monitoring, and food safety. In their Research Article (e202203826), Xue Gao, Yi Zhang and co‐workers developed a new biosensor for amplification‐free nucleic acid detection via harnessing the trans‐cleavage mechanism of Cas13a and ultrasensitive graphene field‐effect transistors (gFETs). The illustration shows the Cas13a‐mediated RNA trans‐cleavage on a gFET surface for sensor signal transduction.

4.
Angewandte Chemie ; 134(32), 2022.
Article in English | ProQuest Central | ID: covidwho-1971219

ABSTRACT

Der Nachweis von Nukleinsäuren spielt eine wichtige Rolle in der medizinischen Diagnostik, der Umweltüberwachung und der Lebensmittelsicherheit. In ihrem Forschungsartikel (e202203826) entwickelten Xue Gao, Yi Zhang und Mitarbeiter einen neuen Biosensor für den amplifikationsfreien Nukleinsäurenachweis, indem sie den trans‐Spaltungsmechanismus von Cas13a und ultrasensitive Graphen‐Feldeffekttransistoren (gFETs) nutzten. Die Abbildung zeigt die Cas13a‐vermittelte RNA‐trans‐Spaltung auf der gFET‐Oberfläche für die Sensorsignalübertragung.

6.
Angewandte Chemie ; n/a(n/a):e202209501, 2022.
Article in English | Wiley | ID: covidwho-1935651

ABSTRACT

Der Nachweis von Nukleinsäuren spielt eine wichtige Rolle in der medizinischen Diagnostik, der Umweltüberwachung und der Lebensmittelsicherheit. In ihrem Forschungsartikel (DOI: 10.1002/ange.202203826) entwickelten Xue Gao, Yi Zhang und Mitarbeiter einen neuen Biosensor für den amplifikationsfreien Nukleinsäurenachweis, indem sie den trans-Spaltungsmechanismus von Cas13a und ultrasensitive Graphen-Feldeffekttransistoren (gFETs) nutzten. Die Abbildung zeigt die Cas13a-vermittelte RNA-trans-Spaltung auf der gFET-Oberfläche für die Sensorsignalübertragung.

7.
Psychiatry and Clinical Neurosciences ; 76(2):41-50, 2022.
Article in English | APA PsycInfo | ID: covidwho-1738334

ABSTRACT

Aims: The Covid-19 pandemic has had a substantial impact on the mental health of the general public and high-risk groups worldwide. Due to its proximity and close links to China, Southeast Asia was one of the first regions to be affected by the outbreak. The aim of this systematic review was to evaluate the prevalence of anxiety, depression and insomnia in the general adult population and healthcare workers (HCWs) in Southeast Asia during the course of the first year of the pandemic. Methods: Several literature databases were systemically searched for articles published up to February 2021 and two reviewers independently evaluated all relevant studies using pre-determined criteria. The prevalence rates of mental health symptoms were calculated using a random-effect meta-analysis model. Results: In total, 32 samples from 25 studies with 20 352 participants were included. Anxiety was assessed in all 25 studies and depression in 15 studies with pooled prevalence rates of 22% and 16%, respectively. Only two studies assessed insomnia, which was estimated at 19%. The prevalence of anxiety and depression was similar among frontline HCWs (18%), general HCWs (17%), and students (20%) while being noticeably higher in the general population (27%). Conclusions: This is the first systematic review to investigate the mental health impact of the Covid-19 pandemic in Southeast Asia. A considerable proportion of the general population and HCWs reported mild to moderate symptoms of anxiety and depression;the pooled prevalence rater, however, remain significantly lower than those reported in other areas such as China and Europe. (PsycInfo Database Record (c) 2022 APA, all rights reserved)

8.
Preprint in English | medRxiv | ID: ppmedrxiv-22272062

ABSTRACT

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with immune escape ability raises the urgent need for developing cross-neutralizing vaccines against the virus. NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen. Here, we evaluated the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in adults previously vaccinated with the inactivated vaccine BBIBP-CorV in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates (NCT05069129). Three groups of healthy adults over 18 years of age (600 participants per group) who had administered two doses of BBIBP-CorV 4-6-month, 7-9-month and >9-month earlier, respectively, were vaccinated with either a homologous booster of BBIBP-CorV or a heterologous booster of NVSI-06-08. The primary outcome was immunogenicity and safety of booster vaccinations. The exploratory outcome was cross-reactive immunogenicity against multiple SARS-CoV-2 variants of concerns (VOCs). The incidence of adverse reactions was low in both booster vaccinations, and the overall safety profile of heterologous boost was quite similar to that of homologous boost. Heterologous NVSI-06-08 booster was immunogenically superior to homologous booster of BBIBP-CorV. Both Neutralizing and IgG antibodies elicited by NVSI-06-08 booster were significantly higher than by the booster of BBIBP-CorV against not only SARS-CoV-2 prototype strain but also multiple VOCs. Especially, the neutralizing activity induced by NVSI-06-08 booster against the immune-evasive Beta variant was no less than that against the prototype strain, and a considerable level of neutralizing antibodies against Omicron (GMT: 367.67; 95%CI, 295.50-457.47) was induced by heterologous booster, which was substantially higher than that boosted by BBIBP-CorV (GMT: 45.03; 95%CI, 36.37-55.74). Our findings showed that NVSI-06-08 was safe and immunogenic as a booster dose following two doses of BBIBP-CorV, which was immunogenically superior to homologous boost with another dose of BBIBP-CorV. Our study also indicated that the design of hybrid antigen may provide an effective strategy for broad-spectrum vaccine developments.

9.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-323625

ABSTRACT

Electric vehicles (EVs) represent a major path for global decarbonization, improvement of air quality and promotion of renewable energy. To tackle the COVID-19 pandemic, China imposed full lockdowns and thorough travel restrictions. This event represents an unprecedented inadvertent geoengineering experiment in vehicle emissions, emulating transition to EVs. Here we novelly exploited observations of air quality during the full lockdown to constrain predictions of a comprehensive chemical transport model. Large traffic flux reductions were near-linearly linked to reductions of NO 2 and PM 2.5 (correlation = 0.491 ~ 0.626). Extrapolating to a full conversion to EV results in a large reduction of PM 2.5 (30 ~ 70%) in most of central and south eastern China. A smaller reduction of PM 2.5 (10 ~ 20%) in Beijing and Tianjin was achievable due to the presence of major industrial emission sources which cause haze at a regional scale. The potential reductions in NO 2 were 40 ~ 90% in most of the megacities. At this present crossroads of policy, our findings reveal timely evidence supporting the transition towards renewable energy.Funding: This study is supported by the Department of Science and Technology of China (No. 2016YFC0202702, 2018YFC0213506 and 2018YFC0213503), National Research Program for Key Issues in Air Pollution Control in China (No. DQGG0107) and National Natural Science Foundation of China (No. 21577126, 41561144004, 21625701). Pengfei Li is supported by Initiation Fund for Introducing Talents of Hebei Agricultural University (412201904) and Youth Top Fund of Universities in Hebei Province (BJ2020032). Conflict of Interest: Authors declare no competing interests.

10.
Preprint in English | medRxiv | ID: ppmedrxiv-21268499

ABSTRACT

BackgroundThe increased coronavirus disease 2019 (COVID-19) breakthrough cases pose the need of booster vaccinations. In this study, we reported the safety and immunogenicity of a heterologous boost with a recombinant COVID-19 vaccine (CHO cells), named NVSI-06-07, as a third dose in participants who have previously received two doses of the inactivated vaccine (BBIBP-CorV) at pre-specified time intervals. Using homologous boost with BBIBP-CorV as control, the safety and immunogenicity of the heterologous boost with NVSI-06-07 against various SARS-CoV-2 strains, including Omicron, were characterized. MethodsThis study is a single-center, randomised, double-blinded, controlled phase 2 trial for heterologous boost of NVSI-06-07 in BBIBP-CorV recipients from the United Arab Emirates (UAE). Healthy adults (aged [≥]18 years) were enrolled and grouped by the specified prior vaccination interval of BBIBP-CorV, i.e., 1-3 months, 4-6 months or [≥]6 months, respectively, with 600 individuals per group. For each group, participants were randomly assigned at 1:1 ratio to receive either a heterologous boost of NVSI-06-07 or a homologous booster dose of BBIBP-CorV. The primary outcome was to comparatively assess the immunogenicity between heterologous and homologous boosts at 14 and 28 days post-boosting immunization, by evaluation of the geometric mean titers (GMTs) of IgG and neutralizing antibodies as well as the corresponding seroconversion rate ([≥]4-fold rise in antibody titers). The secondary outcomes were the safety profile of the boosting strategies within 30 days post vaccination. The exploratory outcome was the immune efficacy against Omicron and other variants of concern (VOCs) of SARS-CoV-2. This trial is registered with ClinicalTrials.gov, NCT05033847. FindingsA total of 1800 individuals who have received two doses of BBIBP-CorV were enrolled, of which 899 participants received a heterologous boost of NVSI-06-07 and 901 received a homologous boost for comparison. No vaccine-related serious adverse event (SAE) and no adverse events of special interest (AESI) were reported. 184 (20{middle dot}47%) participants in the heterologous boost groups and 177 (19{middle dot}64%) in the homologous boost groups reported at least one adverse reaction within 30 days. Most of the local and systemic adverse reactions reported were grades 1 (mild) or 2 (moderate), and there was no significant difference in the overall safety between heterologous and homologous boosts. Immunogenicity assays showed that the seroconversion rates in neutralizing antibodies against prototype SARS-CoV-2 elicited by heterologous boost were 89{middle dot}96% - 97{middle dot}52% on day 28 post-boosting vaccination, which was much higher than what was induced by homologous boost (36{middle dot}80% - 81{middle dot}75%). Similarly, in heterologous NVSI-06-07 booster groups, the neutralizing geometric mean titers (GMTs) against the prototype strain increased by 21{middle dot}01 - 63{middle dot}85 folds from baseline to 28 days post-boosting vaccination, whereas only 4{middle dot}20 - 16{middle dot}78 folds of increases were observed in homologous BBIBP-CorV booster group. For Omicron variant, the neutralizing antibody GMT elicited by the homologous boost of BBIBP-CorV was 37{middle dot}91 (95%CI, 30{middle dot}35-47{middle dot}35), however, a significantly higher level of neutralizing antibodies with GMT 292{middle dot}53 (95%CI, 222{middle dot}81-384{middle dot}07) was induced by the heterologous boost of NVSI-06-07, suggesting that it may serve as an effective boosting strategy combating the pandemic of Omicron. The similar results were obtained for other VOCs, including Alpha, Beta and Delta, in which the neutralizing response elicited by the heterologous boost was also significantly greater than that of the homologous boost. In the participants primed with BBIBP-CorV over 6 months, the largest increase in the neutralizing GMTs was obtained both in the heterologous and homologous boost groups, and thus the booster vaccination with over 6 months intervals was optimal. InterpretationOur findings indicated that the heterologous boost with NVSI-06-07 was safe, well-tolerated and immunogenic in adults primed with a full regimen of BBIBP-CorV. Compared to homologous boost with a third dose of BBIBP-CorV, incremental increases in immune responses were achieved by the heterologous boost with NVSI-06-07 against SARS-CoV-2 prototype strain, Omicron variant, and other VOCs. The heterologous BBIBP-CorV/NVSI-06-07 prime-boosting vaccination may be valuable in preventing the pandemic of Omicron. The optimal booster strategy was the heterologous boost with NVSI-06-07 over 6 months after a priming with two doses of BBIBP-CorV. Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed for clinical trials or prospective/cohort studies involving heterologous booster vaccination in non-immunocompromised population published up to Dec 25, 2021, using the term "(COVID) AND (vaccin*) AND (clinical trial OR cohort OR prospective) AND (heterologous) AND (booster OR prime-boost OR third dose)" with no language restrictions. Nine studies of heterologous prime-boost vaccinations with adenovirus-vector vaccines (ChAdOx1 nCov-19, Oxford-AstraZeneca, Ad26.COV2.S, Janssen) and mRNA vaccines (BNT162b2, Pfizer-BioNtech; mRNA1273, Moderna) were identified. The adenovirus-vector and mRNA heterologous prime-boost vaccination was found to be well tolerated and immunogenic. In individuals primed with adenovirus-vector vaccine, mRNA booster vaccination led to greater immune response than homologous boost. However, varied results were obtained on whether heterologous boost was immunogenically superior to the homologous mRNA prime-boost vaccination. Besides that, A preprint trial in population previously immunized with inactivated vaccines (CoronaVac, Sinovac Biotech) showed that the heterologous boost with adenovirus-vector vaccine (Convidecia, CanSino Biologicals) was safe and induced higher level of live-virus neutralizing antibodies than by the homogeneous boost. A pilot study reported that boosting with BNT162b2 in individuals primed with two doses of inactivated vaccines (BBIBP-CorV) was significantly more immunogenic than homologous vaccination with two-dose of BNT162b2. In addition, a preprint paper demonstrated that heterologous boost of ZF2001, a recombinant protein subunit vaccine, after CoronaVac or BBIBP-CorV vaccination potently improved the immunogenicity. But only a small size of samples was tested in this study and the live-virus neutralization was not detected. Till now, it is still lacking a formal clinical trial to evaluate the immunogenicity and safety of the heterologous prime-boost vaccination with an inactivated vaccine followed by a recombinant protein subunit-based vaccine. Added value of this studyTo our knowledge, this is the first reported result of a large-scale randomised, controlled clinical trial of heterologous prime-boost vaccination with an inactivated vaccine followed by a recombinant protein subunit vaccine. This trial demonstrated that the heterologous prime-booster vaccination with BBIBP-CorV/NVSI-06-07 is safe and immunogenic. Its immunoreactivity is similar to that of homologous vaccination with BBIBP-CorV. Compared to homologous boost, heterologous boost with NVSI-06-07 in BBIBP-CorV recipients elicited significantly higher immunogenicity not only against the SARS-CoV-2 prototype strain but also against Omicron and other variants of concern (VOCs). Implications of all the available evidenceBooster vaccination is considered an effective strategy to improve the protection efficacy of COVID-19 vaccines and control the epidemic waves of SARS-CoV-2. Data from our trial suggested that the booster vaccination of NVSI-06-07 in BBIBP-CorV recipients significantly improved the immune responses against various SARS-CoV-2 strains, including Omicron. Due to no Omicron-specific vaccine available currently, the BBIBP-CorV/NVSI-06-07 heterologous prime-boost might serve as an effective strategy combating Omicron variant. Besides that, BBIBP-CorV has been widely inoculated in population, and thus further boosting vaccination with NVSI-06-07 is valuable in preventing the COVID-19 pandemic. But further studies are needed to assess the long-term protection of BBIBP-CorV/NVSI-06-07 prime-booster vaccination.

11.
Environmental Chemistry Letters ; : 1-11, 2021.
Article in English | EuropePMC | ID: covidwho-1489817

ABSTRACT

Despite large decreases of emissions of air pollution during the coronavirus disease 2019 (COVID-19) lockdown in 2020, an unexpected regional severe haze has still occurred over the North China Plain. To clarify the origin of this pollution, we studied air concentrations of fine particulate matter (PM2.5), NO2, O3, PM10, SO2, and CO in Beijing, Hengshui and Baoding during the lockdown period from January 24 to 29, 2020. Variations of PM2.5 composition in inorganic ions, elemental carbon and organic matter were also investigated. The HYSPLIT model was used to calculate backward trajectories and concentration weighted trajectories. Results of the cluster trajectory analysis and model simulations show that the severe haze was caused mainly by the emissions of northeastern non-stopping industries located in Inner Mongolia, Liaoning, Hebei, and Tianjin. In Beijing, Hengshui and Baoding, the mixing layer heights were about 30% lower and the maximum relative humidity was 83% higher than the annual averages, and the average wind speeds were lower than 1.5 m s−1. The concentrations of NO3−, SO42−, NH4+, organics and K+ were the main components of PM2.5 in Beijing and Hengshui, while organics, K+, NO3−, SO42−, and NH4+ were the main components of PM2.5 in Baoding. Contrary to previous reports suggesting a southerly transport of air pollution, we found that northeast transport caused the haze formation. Supplementary Information The online version contains supplementary material available at 10.1007/s10311-021-01314-8.

12.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-291394

ABSTRACT

Objectives: To analyze the operation status and data over the last 8 years of operation of the first human milk bank (HMB) in East China.MethodsData related to the costs, donors, donation, pasteurization, and recipients were extracted from the web-based electronic monitoring system of the HMB for the period August 1, 2013 to July 31, 2021. ResultsOver the 8 years of operation, 1,555 qualified donors donated 7,396.5 L of qualified milk at a cost of ¥1.94 million, with the average cost per liter of donor human milk being ¥262.3. The donors were between 25 and 30 years of age, and the majority (80.1%) were primipara. All the donated milk was pasteurized and subjected to bacteriological tests before and after pasteurization: 95.4% passed the pre-pasteurization tests, and 96.3% passed the post-pasteurization tests. A total of 9,207 newborns received 5,775.2 L of pasteurized donor milk. The main reason for the prescription of donor human milk was preterm birth. As a result of continuous quality improvements, January 2016 witnessed a significant increase in the volume of qualified DHM and the number of qualified donors. However, in 2020, as a result of the restrictions related to the COVID-19 pandemic, the volume of qualified DHM and the number of qualified donors decreased. Conclusions

13.
Preprint in English | medRxiv | ID: ppmedrxiv-21256078

ABSTRACT

A significant number of individuals experience physical, cognitive, and mental health symptoms in the months after acute infection with SARS-CoV-2, the virus that causes COVID-19. This study assessed depressive and anxious symptoms, cognition, and brain structure and function in participants with symptomatic COVID-19 confirmed by PCR testing (n=100) approximately three months following infection, leveraging self-report questionnaires, objective neurocognitive testing, and structural and functional neuroimaging data. Preliminary results demonstrated that over 1/5 of our cohort endorsed clinically significant depressive and/or anxious symptoms, and >40% of participants had cognitive impairment on objective testing across multiple domains, consistent with brain-fog. While depression and one domain of quality of life (physical functioning) were significantly different between hospitalized and non-hospitalized participants, anxiety, cognitive impairment, and most domains of functioning were not, suggesting that the severity of SARS-CoV-2 infection does not necessarily relate to the severity of neuropsychiatric outcomes and impaired functioning in the months after infection. Furthermore, we found that the majority of participants in a subset of our cohort who completed structural and functional neuroimaging (n=15) had smaller olfactory bulbs and sulci in conjunction with anosmia. We also showed that this subset of participants had dysfunction in attention network functional connectivity and ventromedial prefrontal cortex seed-based functional connectivity. These functional imaging dysfunctions have been observed previously in depression and correlated with levels of inflammation. Our results support and extend previous findings in the literature concerning the neuropsychiatric sequelae associated with long COVID. Ongoing data collection and analyses within this cohort will allow for a more comprehensive understanding of the longitudinal relationships between neuropsychiatric symptoms, neurocognitive performance, brain structure and function, and inflammatory and immune profiles.

14.
One Earth ; 4(7):1037-1048, 2021.
Article in English | ScienceDirect | ID: covidwho-1322298

ABSTRACT

Summary Transportation contributes to around one-fifth of global greenhouse gas emissions, while also causing severe air pollution. The conversion to electric vehicles (EVs) represents a major path to decarbonize the transport sector, with potentially significant co-benefits for human health. However, the scale of such co-benefits largely remains an empirical question and lacks observational evidence. The full lockdown in China during the coronavirus disease 2019 (COVID-19) pandemic provides an unprecedented real-world experiment to evaluate emission reduction potentials of a large-scale transition to EVs. Here, we utilize ground and satellite observations of air quality during the full lockdown to constrain predictions of a comprehensive chemical transport model and find that the substantial traffic reductions are near-linearly linked to reductions of PM2.5 (particles with an aerodynamic diameter ≤2.5 μm) and NO2. A further extrapolation of a full conversion to EVs shows a significant reduction of PM2.5 (30%–70%) and NO2 (30%–80%) in most of China. Our findings provide fact-based evidence of potential environmental benefits generated by fully switching to EVs.

15.
International Feminist Journal of Politics ; : 1-6, 2021.
Article in English | Taylor & Francis | ID: covidwho-1243433
16.
Management and Organization Review ; 16(5):981-985, 2020.
Article in English | ProQuest Central | ID: covidwho-1019670

ABSTRACT

[...]YDCL expanded its delivery group through role shifting (e.g., providing training of professional delivery to employees previously taking non-essential roles). [...]it asked professional operators responsible for analyzing samples and transmitting results to rotate duties, thus enlarging testing volume. Noticing the potential disruptions of COVID-19, YunKang immediately coordinated its global supply chain to import medical equipment and medical consumables. [...]it effectively managed its human capital by relying on interpersonal trust among employees, paramount to achieving positive outcomes in a volatile environment during the crisis. [...]to achieve timely and flexible behavioral responses to a crisis, an organization must be equipped with action options

17.
SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-4740

ABSTRACT

A review. Efficacy and clin. symptoms disappearance rate of Lianhua Qingwen combined with Western medicine on COVID-19 general type patients were statistically analyzed by single rate without control Meta-anal., which could systematically evaluate the clin. efficacy and safety. A systematic search of literatures in PubMed, CNKI, WanFang and VIP for clin. trial on the treatment of COVID-19 with Lianhua Qingwen combined with Western Medicine. RevMan5.3 software was used for statistical anal. of the literature that met the inclusion criteria. Four articles met the requirements, totaling 181 COVID-19 patients. Systematic review results showed that Lianhua Qingwen combined with Western medicine has high effective cure rate which is 0.83, 95%CI(0.72,0.95). Fever disappearance rate is 0.88,95%CI (0.78,0.98), Cough disappearance rate is 0.67,95%CI (0.57,0.78) and weakness disappearance rate is 0.69,95%CI (0.54,0.84). Fever disappearance rate was higher than cough and fatigue (P <0.05). Chest tightness disappearance rate was 0.72, 95% CI (0.58, 0.85), anorexia disappearance rate was 0.34, 95% CI (0.20, 0.47), and expectoration disappearance rate was 0.59, 95% CI (0.42, 0.75). Anorexia disappearance rate was lower than chest tightness and expectoration (P <0.05). None of the included studies had new symptoms of discomfort or worsened signs after oral Lianhua Qingwen treatment. Lianhua Qingwen combined with Western medicine scheme has a higher effective rate for COVID-19 general type patients without obvious adverse reactions, and can significantly cure the main symptoms,especially fever, and representative complications

18.
Journal of Third Military Medical University ; 42(18):1823-1829, 2020.
Article in Chinese | GIM | ID: covidwho-1005499

ABSTRACT

Objective: To analyze the characteristics of risk perception of military personnel in different areas during the early stage of COVID-19 outbreak.

19.
Journal of Third Military Medical University ; 42(16):1619-1624, 2020.
Article in Chinese | CAB Abstracts | ID: covidwho-976630

ABSTRACT

Objective: To investigate the risk perception of coronavirus disease 2019 (COVID-19) among young military personnel serving in high-altitude regions in the early stage of COVID-19 outbreak.

20.
Preprint in English | medRxiv | ID: ppmedrxiv-20173799

ABSTRACT

BackgroundThe present study aim to comprehensively report the epidemiological and clinical characteristics of the COVID-19 patients and to develop a multi-feature fusion model for predicting the critical ill probability. MethodsIt was a retrospective cohort study that incorporating the laboratory-confirmed COVID-19 patients in the Chongqing Public Health Medical Center. The prediction model was constructed with least absolute shrinkage and selection operator (LASSO) logistic regression method and the model was further tested in the validation cohort. The performance was evaluated by the receiver operating curve (ROC), calibration curve and decision curve analysis (DCA). ResultsA total of 217 patients were included in the study. During the treatment, 34 patients were admitted to intensive care unit (ICU) and no developed death. A model incorporating the demographic and clinical characteristics, imaging features and laboratory findings were constructed to predict the critical ill probability and it was proved to have good calibration, discrimination ability and clinic use. ConclusionsThe prevalence of critical ill was relatively high and the model may help the clinicians to identify the patients with high risk for developing the critical ill, thus to conduct timely and targeted treatment to reduce the mortality rate.

SELECTION OF CITATIONS
SEARCH DETAIL